Upgrade to SI Premium - Free Trial

Seattle Genetics (SGEN) Granted FDA Approves for Peripheral T-cell Lymphoma Treatment

November 16, 2018 10:49 AM
The U.S. Food and Drug Administration today expanded the approved use of Seattle Genetics' (NASDAQ: SGEN) Adcetris (brentuximab vedotin) injection ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA

Next Articles